Not publicly disclosed

About Visirna Therapeutics

A biotech company developing RNA-targeted small molecule drugs for oncology and genetic diseases.

About Sanyou Biopharmaceuticals

A Chinese biotech developing novel antibody therapeutics for oncology and immunology using proprietary discovery platforms.

About Sanyou Biopharmaceuticals

A Chinese biotech developing novel antibody therapeutics for oncology and immunology using proprietary discovery platforms.

About OPM Biosciences

A proteomics-focused biotech using mass spectrometry and AI to discover novel biologic targets for oncology and immunology therapies.

About OPM Biosciences

A proteomics-focused biotech using mass spectrometry and AI to discover novel biologic targets for oncology and immunology therapies.

About Ohmic Biosciences

A biotech company developing Molecular Glue Degraders to target and eliminate previously undruggable disease-causing proteins.

About Cerecin

Cerecin is a neuroscience-focused biotech advancing a pipeline of small molecule drugs for neurological conditions like epilepsy and Alzheimer's disease. Operating as a private, pre-revenue entity, the company appears to be in the clinical development stage, leveraging pharmacological approaches to modulate brain metabolism and function. While specific pipeline details are not publicly disclosed on its minimal website, its targeted therapeutic areas represent large, high-need markets with substantial commercial potential. The company's success will hinge on clinical data, strategic partnerships, and securing further funding to advance its programs.

About Cerecin

Cerecin is a neuroscience-focused biotech advancing a pipeline of small molecule drugs for neurological conditions like epilepsy and Alzheimer's disease. Operating as a private, pre-revenue entity, the company appears to be in the clinical development stage, leveraging pharmacological approaches to modulate brain metabolism and function. While specific pipeline details are not publicly disclosed on its minimal website, its targeted therapeutic areas represent large, high-need markets with substantial commercial potential. The company's success will hinge on clinical data, strategic partnerships, and securing further funding to advance its programs.

About Asante Bio

Asante Bio, founded in 2018 and based in Cambridge, USA, is a private, pre-revenue biotechnology company pioneering regenerative orthobiologic implants. Its core innovation lies in additive biomanufacturing platforms that process natural biopolymers into high-strength, disruptive medical devices designed for joint preservation. The company targets high-growth orthopedic indications with a strategy anchored in proprietary biomaterials, domestic manufacturing, and collaboration with a world-class surgeon-developer faculty to revolutionize value-based care.

About insitro

insitro is a private, pre-revenue biotech company pioneering an AI/ML-driven platform for drug discovery. The company combines automated laboratory-generated cellular data with human cohort data to build phenotypic disease models, aiming to identify causal biology and derisk therapeutic development. It is building a wholly-owned and partnered pipeline in metabolism, oncology, and neuroscience, positioning itself at the intersection of cutting-edge biology, data science, and therapeutics. Led by renowned AI researcher Daphne Koller, insitro has secured significant venture funding and major pharmaceutical partnerships to validate its approach.

About CreaGen

CreaGen is a private, pre-revenue biotech firm leveraging its proprietary drug delivery technologies to create enhanced small molecule therapeutics. The company's platform is designed to address key challenges in drug development, such as solubility, bioavailability, and targeted delivery. Its pipeline includes pre-clinical programs targeting oncology and other therapeutic areas, positioning it to potentially create significant value through partnerships or internal development. The company operates with a lean structure, supported by venture capital and strategic collaborations.

About HighPassBio

HighPassBio is a private, pre-clinical stage biotech founded in 2018, pioneering T-cell receptor (TCR) therapies for oncology. The company is developing a pipeline of engineered T-cell therapies aimed at challenging solid tumor targets, positioning itself in the competitive but high-potential cell therapy space. As a pre-revenue entity, its success hinges on advancing its lead programs into clinical trials and securing strategic partnerships or additional funding. Key challenges include navigating complex manufacturing, demonstrating clinical efficacy, and differentiating within a crowded field of cell and gene therapies.

About Mural Oncology

Mural Oncology is a newly formed, clinical-stage biotech company emerging as a spin-out or asset-focused entity, likely built around a specific cytokine technology platform. The company's core mission is to develop next-generation cytokine immunotherapies for cancer, seeking to improve upon first-generation cytokines like IL-2 by engineering molecules with better therapeutic windows. As a young, pre-revenue company, its near-term value drivers will be clinical data readouts from its initial pipeline programs. Its success hinges on demonstrating both safety and efficacy in its lead candidates to attract potential partnership or further investment.

About Mural Oncology

Mural Oncology is a newly formed, clinical-stage biotech company emerging as a spin-out or asset-focused entity, likely built around a specific cytokine technology platform. The company's core mission is to develop next-generation cytokine immunotherapies for cancer, seeking to improve upon first-generation cytokines like IL-2 by engineering molecules with better therapeutic windows. As a young, pre-revenue company, its near-term value drivers will be clinical data readouts from its initial pipeline programs. Its success hinges on demonstrating both safety and efficacy in its lead candidates to attract potential partnership or further investment.

About Tavotek Biotherapeutics

Tavotek Biotherapeutics is a private, preclinical-stage biotech developing innovative antibody-based drugs for cancer and autoimmune disorders. The company's core strength lies in its proprietary technology platforms designed to generate highly specific and potent multi-specific biologics. As a pre-revenue entity, its success hinges on advancing its pipeline through clinical validation and securing strategic partnerships or additional funding. Tavotek operates in a highly competitive but lucrative market, aiming to address significant unmet medical needs with its novel therapeutic candidates.

About Systems Oncology

Systems Oncology is an AI-driven biotech focused on revolutionizing cancer drug discovery. The company utilizes a proprietary cognitive computing platform to mine disparate datasets, model disease mechanisms, and identify novel therapeutic targets with high precision. Its strategy involves a collaborative model, acquiring and amplifying early-stage assets before out-licensing them to larger pharmaceutical partners. Led by a team with deep experience in genomics, systems biology, and business development, the company operates as a private, pre-revenue entity advancing a pipeline of pre-clinical oncology programs.

About AKSO Biopharmaceutical

AKSO Biopharmaceutical, founded in 2017, is a platform-based, clinical-stage biotech company developing breakthrough protein therapeutics. Its core innovation is the DEEP platform, designed to augment protein-protein interactions to create highly effective mono- and bispecific biologics, antibody-drug conjugates, and novel therapies. With a globally focused leadership team combining deep scientific and financial expertise, the company aims to accelerate drug discovery and address critical unmet medical needs in key therapeutic areas. AKSO is actively seeking strategic partnerships to advance its pipeline and expand its global impact.

About AKSO Biopharmaceutical

AKSO Biopharmaceutical, founded in 2017, is a platform-based, clinical-stage biotech company developing breakthrough protein therapeutics. Its core innovation is the DEEP platform, designed to augment protein-protein interactions to create highly effective mono- and bispecific biologics, antibody-drug conjugates, and novel therapies. With a globally focused leadership team combining deep scientific and financial expertise, the company aims to accelerate drug discovery and address critical unmet medical needs in key therapeutic areas. AKSO is actively seeking strategic partnerships to advance its pipeline and expand its global impact.

About Pantarhei Bioscience

Pantarhei Bioscience is a clinical-stage biotech targeting women's health and endocrinology with a pipeline of biologic drugs. The company appears to be in the early clinical or pre-clinical stages of development, positioning itself in a high-need but often underserved therapeutic area. As a private company, its progress is likely supported by venture capital, grants, and strategic partnerships. Its success hinges on advancing its lead candidates through clinical validation and securing further funding or partnership deals.

About Althera Pharmaceuticals

Althera Pharmaceuticals is a private, pre-revenue biotech firm transitioning from generics to novel drug development in the cardiovascular and metabolic disease space. Based in Dublin, Ireland, the company is in the early stages of building its pipeline, likely at the pre-clinical or discovery phase. Its strategic shift positions it to tackle large, chronic disease markets with high unmet need, though it faces the inherent risks of early-stage R&D and significant competition.

About Prediction BioSciences

Prediction BioSciences is a French biotech founded in 2016, targeting the high-unmet-need areas of stroke and neurodegenerative disorders. The company leverages a multi-pronged technological strategy involving diagnostics and novel therapeutic delivery systems like exosomes. While still in the clinical development stage, it has assembled a team with strong academic and industry experience and is supported by strategic partnerships and public funding.

About Bridge Medicines

Bridge Medicines operates as a unique translational engine, identifying and developing early-stage therapeutic discoveries from its founding academic partners—The Rockefeller University, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medicine. The company's core strategy involves in-licensing high-potential, yet nascent, academic research and providing the specialized expertise and funding necessary to advance these programs through preclinical development and into human clinical trials. By focusing on the critical 'valley of death' between academic discovery and industry investment, Bridge aims to build a diversified pipeline of novel assets in oncology and infectious disease. Its success hinges on its ability to selectively identify transformative science and efficiently shepherd it to clinical proof-of-concept.

About Cytolytics

Cytolytics is a private, preclinical-stage biotech firm pioneering next-generation cell-based immunotherapies for cancer. Operating from Munich, Germany, the company utilizes its proprietary technology platform to engineer immune cells with enhanced anti-tumor capabilities. As a pre-revenue entity, it is likely funded by venture capital and grants, focusing on translating its research into a clinical pipeline. Its success hinges on demonstrating preclinical proof-of-concept, securing further funding, and navigating the complex regulatory pathway for cell therapies.

About Shin Nippon Biomedical Laboratories

Japanese biotech developing nanoparticle drug delivery platforms and diagnostics focused on improving oncology therapeutics.

Therapeutic Areas